Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) and Alector (NASDAQ:ALEC – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, earnings, valuation and dividends.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Cardio Diagnostics and Alector, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| Alector | 2 | 3 | 3 | 0 | 2.12 |
Alector has a consensus price target of $3.62, indicating a potential upside of 44.42%. Given Alector’s stronger consensus rating and higher possible upside, analysts plainly believe Alector is more favorable than Cardio Diagnostics.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
| Alector | -850.13% | -531.03% | -44.00% |
Earnings & Valuation
This table compares Cardio Diagnostics and Alector”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cardio Diagnostics | $10,000.00 | 541.68 | -$6.50 million | ($2.92) | -0.63 |
| Alector | $21.05 million | 13.31 | -$142.93 million | ($1.10) | -2.28 |
Cardio Diagnostics has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Cardio Diagnostics has a beta of 2.28, meaning that its share price is 128% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
Insider and Institutional Ownership
8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 9.0% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 8.3% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Alector beats Cardio Diagnostics on 8 of the 14 factors compared between the two stocks.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
About Alector
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
